Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Valproic Acid × Lymphoid × Clear all

Phase

Phase 1 4 Phase 2 2 Phase NA 1 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 5 Myeloid 2 Thoracic 1 Lymphoid 1 Gastrointestinal 1 Dermatologic 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1

Interventions

Rituximab 139 Cyclophosphamide 135 fludarabine 69 Lenalidomide 60 Vincristine 58 fludarabine phosphate 56 Etoposide 50 Doxorubicin 46 venetoclax 43 Prednisone 43 Cytarabine 40 Dexamethasone 35 Peripheral Blood Stem Cell Transplantation 34 Filgrastim 33 Methotrexate 32 obinutuzumab 31 Bendamustine Hydrochloride 30 ibrutinib 28 Gemcitabine 28 Melphalan 24 Bortezomib 23 pembrolizumab 21 Alemtuzumab 20 Whole-Body Irradiation 18 Radiotherapy 18 Carboplatin 18 Tacrolimus 17 Busulfan 17 Mycophenolic Acid 16 acalabrutinib 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01622439 2018-03-12

VALFRID

Lund University Hospital

Phase 1/2 Completed

Lymphoma, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡